Bioasis Technologies Inc

Siemens to Raise €1.4 Billion Through Strategic Healthineers Stake Sale

3 months ago

• Siemens plans to divest approximately 2.3% stake in Siemens Healthineers, pricing 26.5 million shares at €54.65 each, with strong investor demand exceeding available shares. • The stake sale is strategically aligned with Siemens' financing plan for its $10.6 billion Altair Engineering acquisition, demonstrating the company's portfolio optimization strategy. • The transaction represents part of a larger funding strategy, with Siemens also planning to divest €2.5 billion in Siemens Energy shares to complete the Altair acquisition funding.

DeFloria's AJA001: A Novel Botanical Drug for Autism Spectrum Disorder Advances to Phase 2 Trials

4 months ago

• DeFloria, a joint venture involving Charlotte's Web, is developing AJA001, a multi-cannabinoid botanical drug, for treating Autism Spectrum Disorder (ASD). • AJA001 has completed Phase 1 trials, demonstrating safety and a favorable pharmacokinetic profile, paving the way for Phase 2 studies. • The Phase 2 trials, planned for the second quarter of 2025, will evaluate AJA001's efficacy in children, adolescents, and adults with ASD. • AJA001 represents a unique approach as the first oral systemic full-spectrum botanical drug to navigate the FDA approval process.

DeFloria's AJA001 Shows Promise in Phase 1 Trial for Autism Spectrum Disorder

5 months ago

• DeFloria's AJA001, a multi-cannabinoid botanical drug, demonstrated safety and tolerability in a Phase 1 trial involving 70 healthy volunteers. • The trial showed dose-proportional pharmacokinetics for CBD and THC, with plasma concentrations comparable to existing cannabinoid therapeutics. • AJA001's pharmacodynamic effects correlated with THC levels, supporting doses up to 660 mg/day for Phase 2 trials in ASD patients. • The company plans to submit Phase 1 data to the FDA and initiate Phase 2 trials in Q2 2025 to assess AJA001's impact on ASD symptoms.

Jazz Pharmaceuticals' Epidyolex Fails Phase 3 Trial in Japan for Epilepsy

9 months ago

• Jazz Pharmaceuticals' Epidyolex did not meet its primary endpoint in a Phase 3 trial in Japan for treatment-resistant epilepsies, despite showing numeric improvements. • The trial assessed Epidyolex as an adjunctive treatment for Dravet Syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in pediatric patients. • British American Tobacco's cannabis investments are expected to drive growth, offsetting declines in traditional tobacco revenues through strategic investments like Organigram. • DanCann Pharma reported record revenue and its first positive EBITDA in Q2 2024, driven by increased product sales and strategic cost management.